Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023 Pharmaceutical Investing
Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook Pharmaceutical Investing
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility Life Science Investing
Merck's KEYTRUDA® Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial Life Science Investing
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office Pharmaceutical Investing
Lobe Sciences Board of Directors Elects to Receive Shares in Lieu of Cash for All Board Fees Pharmaceutical Investing
Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023 Pharmaceutical Investing
